Catalent’s Acquisition Of Delphi Genetics

Osborne Clarke has advised Delphi Genetics on the deal.

Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, has been acquired by Catalent through an auction process in coordination with the US-based investment bank, Achelous Partners. The sale was completed with a valuation of the company at 55 million USD.

Founded in 2001 as a spin off from the Université libre de Bruxelles (ULB), Delphi Genetics is a lead-ing bioproduction CDMO with capabilities in handling the entire plasmid DNA development and CGMP manufacturing process. 

Catalent is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products.

The team was led by Partner Hadrien Chef and included Laurent De Pauw (Associate, Corporate), Tonya Aelbrecht (Senior Associate, Corporate), Karen Calvo Vleugels (Junior Associate, Corporate), Benjamin Docquir (Picture – Partner, IT/IP), Chloé Ponsart (Associate, IT/IP), Vinciane Rysselinck (Senior Counsel, Employment) and Olivier Lambillon, (Counsel, Tax).


Involved fees earner: Tonya Aelbrecht – Osborne Clarke; Laurent De Pauw – Osborne Clarke; Benjamin Docquir – Osborne Clarke; Olivier Lambillon – Osborne Clarke; Chloé Ponsart – Osborne Clarke; Vinciane Rysselinck – Osborne Clarke;

Law Firms: Osborne Clarke;

Clients: Delphi Genetics;

Author: Federica Tiefenthaler